26.08.2010 • NewsAllerganBausch & LombBloomberg

Sanofi Won't Go Above $70 per Share for Genzyme

Sanofi-Aventis is not willing to pay more than $70 per share for U.S. biotech Genzyme and may look at alternative targets, Bloomberg reported on Wednesday, citing sources familiar with the matter.

France's Sanofi has offered $69 per share for Genzyme and its board has authorized a bid of up to $70 per share, sources have told press representatives in the past.

According to the Bloomberg report, Sanofi may consider companies such as Bausch & Lomb, Allergan or Celgene if a deal with Genzyme falls through.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.